Key Takeaways Moderna's mRNA-1010 flu shot showed 26.6% better efficacy than GSK's in a phase III trial. Efficacy was strong across strains and age groups, with 27.4% rVE in seniors aged 65 and older. The results may aid future FDA submissions for mRNA-1010 and support the combo vaccine mRNA-1083.Moderna (MRNA) announced that its seasonal influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy (rVE) than an approved flu shot marketed by GSK plc (GSK) in a phase III efficacy stu ...

Moderna says its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of selling combination vaccines https://t.co/93QBuninAV ...

Welcome back. Despite the market nearing new highs here, the healthc care sector is one of the few groups still negative on the year. Also the second worst performer for Q2, just behind energy.UNH, United Healthcare biggest drag on the sector down 42% since the start of April. David. All right.Meanwhile, RFK's new handpicked vaccine advisory committee voting on the RSV vaccine this morning and the flu shot this afternoon. Angelica Peoples has the latest for us. Angelica.Hey, David. That's right. So, in its ...